Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

J&J’s Ethicon completes first robot-assisted kidney stone removal with Monarch platform

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Haemonetics Wins FDA Approval for Vascade...

Haemonetics has secured an expanded regulatory milestone in the...

FDA Clears Medtronic Stealth Axis for...

Medtronic’s Stealth Axis FDA clearance marks an expansion of...

Philips AI DeviceGuide Gets FDA Approval...

Regulatory clearance has been secured by Philips from the...

Ethicon, a Johnson & Johnson MedTech company, today announced the first robotic-assisted removal of kidney stones using the Monarch platform.

Auris Health, an Ethicon subsidiary, received FDA clearance for Monarch for endourological procedures in May 2022. The University of California, Irvine’s UCI Health used the Monarch platform for urology to complete the first procedure.

According to a news release, it’s the first successful robotically assisted, electromagnetic-guided percutaneous access and mini-percutaneous nephrolithotomy procedure. Ethicon said its study involves a collaboration with co-investigator Dr. Mihir Desai from the University of Southern California.

“This clinical study is the first in the world to research and demonstrate the potential for improved navigation, access, clearance and control in mini-PCNL procedures using the Monarch platform for urology,” said Dr. Jaime Landman, chair of the UCI School of Medicine Department of Urology and director of the UCI Health Kidney Stone & Kidney Disease Services. “In addition to potentially helping urologists achieve stone-free patients in a single procedure, this approach could help reduce the need for retreatment after kidney stone removal and decrease risks and complication rates.”

Ethicon’s clinical group led the first case in its clinical study. It aims to collect performance data on robotic mini-PCNL procedures to optimize Monarch and inform training and education.

“The prevalence of kidney stones remains high, and many urologists seek a new treatment option that reduces overall retreatment and complication rates,” Desai said. “In patients who require treatment through surgery, close to one in two will require retreatment within five years.”

MEDICAL FAIR ASIA 2026

Latest stories

Related stories

Haemonetics Wins FDA Approval for Vascade MVP XL System

Haemonetics has secured an expanded regulatory milestone in the...

FDA Clears Medtronic Stealth Axis for Cranial, ENT Uses

Medtronic’s Stealth Axis FDA clearance marks an expansion of...

Philips AI DeviceGuide Gets FDA Approval for Cardiac Use

Regulatory clearance has been secured by Philips from the...

GE HealthCare Drives Cardio-Oncology Care in EU COMPASS

GE HealthCare has taken on the role of lead...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »